How Gleevec changed cancer treatment : NPR
NPR • • health
Key Points:
- Mel Mann was diagnosed with chronic myeloid leukemia in 1995 and given three years to live, but after participating in clinical trials for the drug Gleevec starting in 1998, he experienced a dramatic recovery and is now thriving decades later.
- Gleevec, developed through targeted cancer therapy research led by oncologist Brian Druker, was one of the first drugs to specifically inhibit the abnormal enzyme caused by the Philadelphia chromosome in leukemia cells.
- Clinical trials showed remarkable patient responses with mild side effects, leading to Gleevec's FDA approval in 2001 in a record 72 days, marking a breakthrough in cancer treatment and the beginning of an era of targeted therapies.
- Although initially expensive, Gleevec's cost has decreased significantly with generic versions, improving accessibility while highlighting ongoing challenges in drug pricing and access.
- The success of Gleevec has transformed chronic myeloid leukemia from a fatal diagnosis to a manageable condition, allowing patients to live normal lives, and its development exemplifies effective collaboration between researchers, clinicians, patients, and industry.